STB-C017 is an IDO/TDO dual inhibitor, derived from Syntekabio's proprietary drug discovery artificial intelligence solution, demonstrated powerful immuno-oncologic effect.
Triple combination therapy of STB-C017, PD-1, CTLA-4 immune checkpoint inhibitors (ICIs) presented complete remission (CR) of tumor and long-term survival benefit.
Subsequent nonclinical development and collaborative efforts might yield IND submission within 2 years
Syntekabio (KOSDAQ: 226330), an AI and NGS based drug development company, presented the result of STB-C017 animal experiments, a small molecule IDO/TDO dual inhibitor derived by Syntekabio's AI drug discovery solution, at the 2020 American Association for Cancer Research (AACR) Annual Meeting, today at 00:00 EDT.
Chan Kim, M.D., Ph.D., associate professor
of CHA Bundang Medical Center and the presenter of the research, stated,
"STB-C017 significantly enhanced immuno-oncologic effect compared to
epacadostat. It also derived multiple CRs when combined with ICIs." Hong
Jae Chon, M.D., Ph.D., the principal investigator, said, "Specifically in
renal cell carcinoma, hepatocellular carcinoma, anti-PD-1/CTLA-4 combination is
becoming standard-of-care, so combining STB-C017 on top of those combination
could yield impressive treatment enhancement."
"The result showed significant
feasibility of subsequent development for STB-C017. When the STB-C017 reach
market, those ICIs would be used more broadly, which would give us the
opportunity," said Sunil Youn, M.D., Business Development Director of
Syntekabio.
The presentation with key findings is
titled "Artificial intelligence with a deep learning technology enables a
rational development of a potent immunotherapeutic agent," and includes:
1. STB-C017 effectively blocked
kynurenine secretion from tumor, an immunosuppressor, and showed dose-response
relationship in colorectal cancer mice models.
2. STB-C017 treatment showed
significant infiltrations of CD8+ T cells into the tumor, and reduction of Treg
Cells.
3. STB-C017 dosing regimen
optimized as 5 days of administration & 2 days off
4. Combination therapy with
anti-PD1/CTLA4 markedly delayed tumor growth and induced multiple CRs.
- STB-C017 triple combination induced two-fold increase of CRs
compared to epacadostat triple. Recovered mice acquired long-term
antineoplastic immunity.
- Mice treated with STB-C017 triple combination showed marked
survival benefit compared to the others, including epacadostat triple.
Syntekabio plans subsequent STB-C017
development, including GLP toxicology and animal PKPD, targeting IND
submission, around 1H 2022. The company will execute further translational
research based on firm collaboration with CHA Bundang Hospital and lead the
full scope of the development programs.
About Syntekabio, Inc.
Syntekabio is an AI and NGS based drug
development company, utilizing genomic database and artificial intelligence to
predict and identify new molecular entities to be a relevant new drug product.
It is the global first AI drug development company listed on the public market
(KOSDAQ: 226330) last December. The Company's lead product candidate, STB-C017,
an IDO/TDO dual inhibitor for the treatment of advanced solid tumor, is under
nonclinical development. The company's subsequent pipelines include
personalized neoantigen cancer vaccines, small molecules targeting established
oncology targets, and biomarkers to stratify relevant patients to maximize
treatment efficacy. Syntekabio's business model is to collaborate with various
academic institutions and biopharma companies to optimize development process,
utilizing proprietary AI and NGS data. The Company is headquartered in Daejeon,
Rep. of Korea, with offices in Seoul, Rep. of Korea and Rockville, MD, USA. For
additional information, please visit webpage: http://www.syntekabio.com/
